Tag: RCH
OSE Immuno: end of recruitment of a trial for RCH – 03/18/2024 at 08:01
(CercleFinance.com) – OSE Immunotherapeutics today announces the end of recruitment in the Phase 2b clinical trial evaluating the IL-7 receptor antagonist monoclonal antibody Lusvertikimab (OSE-127) in patients with ulcerative colitis…